StepStone Master G

StepStone Master G, L.P. is a venture capital fund managed by StepStone Group, a global private markets investment firm. The fund specializes in providing capital to companies within the life sciences, biotechnology, and healthcare sectors, often participating in significant financing rounds for clinical-stage biopharmaceutical firms. In March 2026, the fund was a key participant in a $150 million private placement for OnKure Therapeutics to support the development of its PI3Kα pan-mutant selective inhibitor candidates. StepStone Master G leverages the broader StepStone Group platform and its extensive expertise in private equity to identify and back high-potential therapeutic innovations and precision medicine developers. The fund is part of StepStone's broader strategy to invest in healthcare sub-sectors that demonstrate superior risk-adjusted performance and sustained innovation.